 |
16 Products |  |
56 Diseases | | 16 Products |
|
39 Trials |  |
939 News |  |
| «12...234567891011121314» |
- | New trial: MOTIVATE: Treatment of Hemophilia A Patients With FVIII Inhibitors (clinicaltrials.gov) - Jul 16, 2019
P, N=120, Not yet recruiting, Sponsor: Emory University
- | Nuwiq (simoctocog alfa) / Octapharma
Clinical, Review, Journal: Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. (Pubmed Central) - Jul 3, 2019
No FVIII inhibitors were detected in PTPs after treatment with 43,267 injections and >80 million IU of Nuwiq®. Interim data for 66 PUPs with ⩾20 exposure days to Nuwiq® in NuProtect demonstrated a low cumulative high-titer inhibitor rate of 12.8% [actual incidence 12.1% (8/66)] and convincing efficacy and safety.
- ||| Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial completion: Octagam 5% Versus Comparator Post Marketing Trial (clinicaltrials.gov) - Jun 12, 2019
P=N/A, N=623, Completed, Sponsor: Octapharma
Interim data for 66 PUPs with ⩾20 exposure days to Nuwiq® in NuProtect demonstrated a low cumulative high-titer inhibitor rate of 12.8% [actual incidence 12.1% (8/66)] and convincing efficacy and safety. Active, not recruiting --> Completed
- | Gammaplex (intravenous normal human immunoglobulin) / Bio Products Laboratory (BPL), Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion, Octagam (intravenous normal human immunoglobulin) / Octapharma
Journal: Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US. (Pubmed Central) - May 25, 2019
However, differences existed in switch rates for different IVIG products. The reason for low switching rates could not be assessed in this study; therefore, further studies are required to detect possible relevant differences in effectiveness and tolerability.
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial completion, Enrollment change, Head-to-Head, Surgery: FIBRES: FIBrinogen REplenishment in Surgery (clinicaltrials.gov) - May 14, 2019
P3, N=827, Completed, Sponsor: University Health Network, Toronto
The reason for low switching rates could not be assessed in this study; therefore, further studies are required to detect possible relevant differences in effectiveness and tolerability. Active, not recruiting --> Completed | N=1200 --> 827
- |||||||| Gammanorm (human immune globulin subcutaneous) / Octapharma
New P3 trial: Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases (clinicaltrials.gov) - May 5, 2019
P3, N=65, Not yet recruiting, Sponsor: Octapharma
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
Trial initiation date: ATTEND: Autologous Transplant To End NMO Spectrum Disorder (clinicaltrials.gov) - May 2, 2019
P2/3, N=50, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed | N=1200 --> 827 Initiation date: Mar 2019 --> Jun 2019
- | Nuwiq (simoctocog alfa) / Octapharma
Clinical, Journal: Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries. (Pubmed Central) - Apr 30, 2019
Continuous infusion with simoctocog alfa was found to achieve good/excellent haemostatic efficacy in all procedures. No adverse events occurred and no inhibitors developed.
- | Octanate (human Factor VIII/von Willebrand Factor) / Octapharma
Journal: Effect of Silane Treatment on Mechanical Properties of Polyurethane/Mesoscopic Fly Ash Composites. (Pubmed Central) - Apr 27, 2019
In view of the accidents such as rock mass breakage, roof fall and coal slide in coal mines, polyurethane/mesoscopic fly ash (PU/MFA) reinforcement materials were produced from polymethylene polyphenylene isocyanate (PAPI), the polyether polyol, flame retardant, and MFA using stannous octanate as a catalyst...The results show that the compression property, fracture toughness, maximum flexural strength, and bond strength of PU/MFA composites increase by 21.6%, 10.1%, 8.8%, and 19.3%, respectively, compared with the values before the modification. Furthermore, the analyses of scanning electron microscope and dynamic mechanics suggest that the coupling agent GPTMS can successfully improve the mechanical properties of PU/MFA composites because it eliminates the stress concentration and exerts a positive effect on the crosslink density and hardness of PU/MFA composites.
- |||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Enrollment closed: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (clinicaltrials.gov) - Apr 26, 2019
P3, N=142, Active, not recruiting, Sponsor: Octapharma
Furthermore, the analyses of scanning electron microscope and dynamic mechanics suggest that the coupling agent GPTMS can successfully improve the mechanical properties of PU/MFA composites because it eliminates the stress concentration and exerts a positive effect on the crosslink density and hardness of PU/MFA composites. Recruiting --> Active, not recruiting
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Efficacy and safety of a new intravenous immunoglobulin (Panzyga ) in chronic immune thrombocytopenia. (Pubmed Central) - Apr 26, 2019
P3
Recruiting --> Active, not recruiting IVIG 10% is well tolerated even at a high infusion speed and induces a rapid platelet count increase, thus decreasing the bleeding rate and the severity of bleeding events.
- | Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial completion, Trial completion date, Trial primary completion date: Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease (clinicaltrials.gov) - Apr 16, 2019
P2, N=5, Completed, Sponsor: Sutter Health
IVIG 10% is well tolerated even at a high infusion speed and induces a rapid platelet count increase, thus decreasing the bleeding rate and the severity of bleeding events. Enrolling by invitation --> Completed | Trial completion date: May 2019 --> Jul 2018 | Trial primary completion date: Jan 2019 --> Jul 2018
- ||| Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial completion date, Trial primary completion date: ProDERM: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) (clinicaltrials.gov) - Apr 9, 2019
P3, N=94, Active, not recruiting, Sponsor: Octapharma
Enrolling by invitation --> Completed | Trial completion date: May 2019 --> Jul 2018 | Trial primary completion date: Jan 2019 --> Jul 2018 Trial completion date: Mar 2019 --> Oct 2019 | Trial primary completion date: Mar 2019 --> Oct 2019
- | Octagam (intravenous normal human immunoglobulin) / Octapharma
Clinical, Retrospective data, Journal: Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (Pubmed Central) - Mar 26, 2019
These real-life results are consistent with the efficacy and safety of IVIG reported in randomised controlled studies. A long-term prospective study of Octagam in patients with CIDP is warranted.
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
New P4 trial: Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Mar 7, 2019
P4, N=20, Not yet recruiting, Sponsor: Octapharma
- Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial completion date, Trial primary completion date: A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) (clinicaltrials.gov) - Mar 5, 2019
P4, N=21, Active, not recruiting, Sponsor: IMMUNOe Research Centers
A long-term prospective study of Octagam in patients with CIDP is warranted. Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Nov 2018 --> Nov 2019
- || Octagam (intravenous normal human immunoglobulin) / Octapharma
Enrollment closed: Octagam 5% Versus Comparator Post Marketing Trial (clinicaltrials.gov) - Mar 4, 2019
P=N/A, N=623, Active, not recruiting, Sponsor: Octapharma
Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Nov 2018 --> Nov 2019 Recruiting --> Active, not recruiting
- ||||| Nuwiq (simoctocog alfa) / Octapharma
Trial completion, Enrollment change: NuProtect: Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII (clinicaltrials.gov) - Feb 28, 2019
P3, N=48, Completed, Sponsor: Octapharma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=100 --> 48
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
New P2/3 trial: ATTEND: Autologous Transplant To End NMO Spectrum Disorder (clinicaltrials.gov) - Feb 4, 2019
P2/3, N=50, Recruiting, Sponsor: Northwestern University
- |||| Octagam (intravenous normal human immunoglobulin) / Octapharma
Enrollment closed: ProDERM: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) (clinicaltrials.gov) - Jan 9, 2019
P3, N=94, Active, not recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed | N=100 --> 48 Recruiting --> Active, not recruiting
- |||||| Fibryga (fibrinogen concentrate (human)) / Octapharma
New trial: Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Jan 4, 2019
P, N=25, Not yet recruiting, Sponsor: Octapharma
- | New P4 trial: Implementation of pharmacokinetic-guided dosing of prophylaxis in hemophilia patients. Implementatie van farmacokinetisch gestuurd doseren van profylaxe bij hemofilie patienten. (EUDRACT) - Dec 21, 2018
P4, N=50, , Sponsor: Erasmus University Medical Center
- || Nuwiq (simoctocog alfa) / Octapharma
Trial completion date, Trial primary completion date: GENA-99: Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ (clinicaltrials.gov) - Dec 6, 2018
P=N/A, N=200, Recruiting, Sponsor: Octapharma
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | Privigen (human immune globulin intravenous 10%) / CSL Behring, Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion, Octagam (intravenous normal human immunoglobulin) / Octapharma
Enrollment closed, Trial completion date: Ig PRx in AECOPD: Pilot Study (clinicaltrials.gov) - Nov 29, 2018
P2, N=48, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Jun 2020
- | Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial completion: Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A (clinicaltrials.gov) - Nov 26, 2018
P3, N=10, Completed, Sponsor: Octapharma
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Jun 2020 Active, not recruiting --> Completed
- | Nuwiq (simoctocog alfa) / Octapharma
Trial completion date: NuProtect: Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients (clinicaltrials.gov) - Nov 20, 2018
P3, N=110, Active, not recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Enrollment closed, Head-to-Head, Surgery: FIBRES: FIBrinogen REplenishment in Surgery (clinicaltrials.gov) - Nov 1, 2018
P3, N=1200, Active, not recruiting, Sponsor: University Health Network, Toronto
Trial completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- | Balfaxar (prothrombin complex concentrate, human-lans) / Octapharma, Pfizer
Enrollment change, Trial completion date, Trial primary completion date: PCC and Fibrinogen Compared With FFP in PPH (clinicaltrials.gov) - Oct 10, 2018
P4, N=0, Withdrawn, Sponsor: Helsinki University Central Hospital
Recruiting --> Active, not recruiting N=40 --> 0 | Trial completion date: Dec 2014 --> Oct 2018 | Trial primary completion date: Sep 2014 --> Oct 2018
- ||||| Nuwiq (simoctocog alfa) / Octapharma
Trial completion: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - Oct 9, 2018
P3b, N=58, Completed, Sponsor: Octapharma
N=40 --> 0 | Trial completion date: Dec 2014 --> Oct 2018 | Trial primary completion date: Sep 2014 --> Oct 2018 Active, not recruiting --> Completed
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial completion date: Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Oct 2, 2018
P2, N=52, Active, not recruiting, Sponsor: Sutter Health
Active, not recruiting --> Completed Trial completion date: Jul 2018 --> Dec 2018
- | Gammanorm (human immune globulin subcutaneous) / Octapharma
New P4 trial, Pricing: Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment (clinicaltrials.gov) - Sep 19, 2018
P4, N=30, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- | Nuwiq (simoctocog alfa) / Octapharma
Clinical, Journal: Immunogenicity, efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study. (Pubmed Central) - Sep 7, 2018
Trial completion date: Jul 2018 --> Dec 2018 These interim data show a cumulative incidence of 12.8% for HT inhibitors and convincing efficacy and tolerability in PUPs treated with Nuwiq .
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial completion, Trial completion date, Trial primary completion date, HEOR: Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps (clinicaltrials.gov) - Sep 5, 2018
P4, N=31, Completed, Sponsor: Octapharma
These interim data show a cumulative incidence of 12.8% for HT inhibitors and convincing efficacy and tolerability in PUPs treated with Nuwiq . Recruiting --> Completed | Trial completion date: Dec 2017 --> Aug 2017 | Trial primary completion date: Dec 2017 --> Aug 2016
- | Nuwiq (simoctocog alfa) / Octapharma
Trial completion date: GENA-99: Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ (clinicaltrials.gov) - Aug 22, 2018
P=N/A, N=200, Recruiting, Sponsor: Octapharma
Recruiting --> Completed | Trial completion date: Dec 2017 --> Aug 2017 | Trial primary completion date: Dec 2017 --> Aug 2016 Trial completion date: Mar 2020 --> Jun 2019
- | ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment open, Trial initiation date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Aug 1, 2018
P1b, N=150, Recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial completion date: Mar 2020 --> Jun 2019 Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Jul 2018
- | Nuwiq (simoctocog alfa) / Octapharma
Clinical, Journal: Efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures. (Pubmed Central) - Jul 27, 2018
Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Jul 2018 The results of this pooled analysis show that Nuwiq was efficacious in maintaining haemostasis during and after major and minor surgical procedures in PTPs with severe haemophilia A.
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Enrollment closed, Trial completion date, Trial primary completion date: Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A (clinicaltrials.gov) - Jul 26, 2018
P3, N=10, Active, not recruiting, Sponsor: Octapharma
The results of this pooled analysis show that Nuwiq was efficacious in maintaining haemostasis during and after major and minor surgical procedures in PTPs with severe haemophilia A. Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018
- ||| Wilate (human factor VIII/von Willebrand factor) / Octapharma, Nuwiq (simoctocog alfa) / Octapharma
Enrollment open: PREVAIL: Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (clinicaltrials.gov) - Jul 23, 2018
P=N/A, N=80, Recruiting, Sponsor: Octapharma
Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018 Not yet recruiting --> Recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
New P2/3 trial: CAST: Cardiac Safe Transplants for Systemic Sclerosis (clinicaltrials.gov) - Jul 20, 2018
P2/3, N=50, Recruiting, Sponsor: Northwestern University
- |||| Fibryga (fibrinogen concentrate (human)) / Octapharma
New P2 trial, Surgery: Fibrinogen (blood protein) supplementation in patients that have developed fibrinogen deficiency during surgery. (EUDRACT) - Jul 19, 2018
P2, N=55, Ongoing, Sponsor: Octapharma AG
- ||| Octagam (intravenous normal human immunoglobulin) / Octapharma, Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Enrollment open, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: GAM 10-06: Non-Interventional Study on the Tolerability and Efficacy of IVIG (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=500, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P4 --> PN/A | N=1000 --> 500 | Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
- || Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial completion date, Trial primary completion date: Octagam 5% Versus Comparator Post Marketing Trial (clinicaltrials.gov) - Jun 12, 2018
P=N/A, N=500, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting | Phase classification: P4 --> PN/A | N=1000 --> 500 | Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019 Trial completion date: Mar 2018 --> May 2019 | Trial primary completion date: Mar 2018 --> May 2019
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial completion date: Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Jun 7, 2018
P2, N=52, Active, not recruiting, Sponsor: Sutter Health
Trial completion date: Mar 2018 --> May 2019 | Trial primary completion date: Mar 2018 --> May 2019 Trial completion date: Nov 2017 --> Jul 2018
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial completion, HEOR: A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push (clinicaltrials.gov) - Jun 7, 2018
P4, N=30, Completed, Sponsor: Octapharma
Trial completion date: Nov 2017 --> Jul 2018 Recruiting --> Completed
- || Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial completion, Trial completion date, Trial primary completion date, Surgery: FORMA-02: Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery (clinicaltrials.gov) - Jun 7, 2018
P3, N=25, Completed, Sponsor: Octapharma
Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: May 2018 --> Jan 2018 | Trial primary completion date: May 2018 --> Jan 2018
- || Wilate (human factor VIII/von Willebrand factor) / Octapharma, Nuwiq (simoctocog alfa) / Octapharma
Trial completion date, Trial primary completion date: PREVAIL: Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (clinicaltrials.gov) - Jun 7, 2018
P=N/A, N=80, Not yet recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed | Trial completion date: May 2018 --> Jan 2018 | Trial primary completion date: May 2018 --> Jan 2018 Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
- || ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial initiation date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - May 1, 2018
P1b, N=150, Not yet recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027 Initiation date: Mar 2018 --> Dec 2018
- ||||| Nuwiq (simoctocog alfa) / Octapharma
Enrollment closed, Trial completion date, Trial primary completion date: NuProtect: Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII (clinicaltrials.gov) - Apr 18, 2018
P3, N=100, Active, not recruiting, Sponsor: Octapharma
Initiation date: Mar 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Trial completion date: Apr 2018 --> Dec 2018 | Trial primary completion date: Apr 2018 --> Dec 2018
- ||||||| Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial completion: Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A (clinicaltrials.gov) - Apr 18, 2018
P3, N=55, Completed, Sponsor: Octapharma
Recruiting --> Active, not recruiting | Trial completion date: Apr 2018 --> Dec 2018 | Trial primary completion date: Apr 2018 --> Dec 2018 Active, not recruiting --> Completed
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Enrollment closed, Trial completion date, Trial primary completion date, Surgery: FORMA-02: Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery (clinicaltrials.gov) - Apr 13, 2018
P3, N=24, Active, not recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: Oct 2019 --> May 2018